Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get in-depth healthcare industry analysis with the unparalleled resources at Informa Pharma Intelligence.
Download your copy of this essential whitepaper, which provides a window into the rapidly evolving world of personalized medicine, and the accompanying outlook for related clinical trials.
One Size No Longer Fits All: The Personalized Medicine Trial Landscape includes:
Scrip
By Sten Stovall 23 Oct 2019
VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
Scrip
By Kevin Grogan 23 Oct 2019
Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
Datamonitor Healthcare
By Hannah Cohen 21 Oct 2019
Explore the key hurdles to anticipating the initial and potential value of the NASH therapy market.
Scrip
By Alex Shimmings 18 Oct 2019
Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.
Scrip
By Brian Yang 18 Oct 2019
Multinationals are feeling the heat to win in China's latest drug procurement battle. The winning prices have surprised even previous winners and may have a profound and long-lasting impact on the pharma sector.
Topic Deal trends Strategy
Scrip
By Andrew McConaghie 18 Oct 2019
Investor's Downfall is Unwelcome Distraction: As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
Scrip
By Mandy Jackson 18 Oct 2019
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Scrip
By Andrew McConaghie 18 Oct 2019
Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting.
Topic Research BioPharmaceutical
Scrip
By Mandy Jackson 18 Oct 2019
One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
Topic Cell and gene therapy
Biomedtracker, Meddevicetracker
16 Oct 2019
What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.
Meddevicetracker
16 Oct 2019
What were the outcomes of critical catalysts featured in Meddevicetracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.
Topic Drug approval
Biomedtracker
16 Oct 2019
What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.
Topic Drug approval Drug review FDA
Pink Sheet
16 Oct 2019
When you look at newly approved drugs, the latest product reviews and the decisions made during the process, you can gain critical insights to inform your own strategic decisions. That’s what Pink Sheet delivers, and now you can try it for free.
Pink Sheet
16 Oct 2019
Keep track of compliance, legislation, policy regulations, and industry developments with the expertise of our worldwide network of expert analysts and journalists on the ground in key global regions.
Scrip
14 Oct 2019
Find out how the consequences of the opioids crisis is affecting the pharma industry, from shaping the way deals are made, to transforming the development of new categories of drugs. Scrip brings you the implications behind the headlines in an essential free article pack.
Pink Sheet
23 Oct 2019
Pink Sheet
23 Oct 2019
Medtech Insight
23 Oct 2019
Medtech Insight
23 Oct 2019
Scrip
23 Oct 2019
Scrip
23 Oct 2019
Medtech Insight
23 Oct 2019
Pink Sheet
23 Oct 2019
Pink Sheet
23 Oct 2019
Pink Sheet
23 Oct 2019
Pink Sheet
23 Oct 2019
Scrip
23 Oct 2019
Pink Sheet
23 Oct 2019
Pink Sheet
23 Oct 2019
Scrip
23 Oct 2019
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
